Design Therapeutics Inc (DSGN) Stock Price, Quote & News

Company Profile

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progr...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 293 4900

Website: www.designtx.com

Address:

6005 Hidden Valley Road, Suite 110, Carlsbad, United States

SuperGreenToday May. 19 at 12:55 AM

$DSGN Share Price: $10.70 Contract Selected: Dec 18, 2026 $10 Calls Buy Zone: $2.63 – $3.26 Target Zone: $4.47 – $5.46 Potential Upside: 60% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Arcides May. 18 at 5:28 PM

$DSGN down 51% from premarket high

1 · Reply

Olivia_Strickland May. 18 at 4:35 PM

$DSGN down 26% on the morning and my scanner is calling it a "breakout," which at this point I'm just gonna assume is sarcasm. they dropped four-week Friedreich Ataxia data last night and the market's verdict is apparently "thanks but no thanks," because that's a $14 stock trading with a 10 handle on 7.8x avg vol. biotech data prints are the one place where I genuinely have no edge, but I do know what a -26% candle on the news day usually means for the rest of the week. anyone here actually read the readout and have a take on whether this is an overreaction or the start of a longer bleed? structure breaking on the chart: https://tapeboard.com/chart/DSGN?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=dsgn-bk-dn-chart

1 · Reply

Arcides May. 18 at 3:43 PM

$DSGN

0 · Reply

laaarsas May. 18 at 3:32 PM

$DSGN Why down today?

0 · Reply

OptionRunners May. 18 at 12:58 PM

$DSGN +10% on data

0 · Reply

notreload_ai May. 18 at 12:45 PM

$DSGN DT-216P2 improved Friedreich ataxia symptoms in early trial, increased frataxin levels and was well tolerated with no serious side effects. https://notreload.xyz/xy/dt-216p2-shows-rapid-4-week-gains-in-friedreich-ataxia/

0 · Reply

OpenOutcrier May. 18 at 12:40 PM

$DSGN (+7.9% pre) Design Therapeutics reports positive trial data for Friedreich ataxia drug https://ooc.bz/l/102670

0 · Reply

focafoca99 May. 17 at 10:44 PM

$DSGN hosts a webcast on May 18 to review RESTORE-FA trial data for DT-216P2.

0 · Reply

AlertsAndNews May. 17 at 10:06 PM

$DSGN dropping data tomorrow morning according to the company. Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026 "will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET."

0 · Reply

Design Therapeutics Transcript: Status update

2026-05-18T11:36:34.000Z - 17 hours ago

Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial

May 18, 2026, 7:00 AM EDT - 17 hours ago

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

May 17, 2026, 4:00 PM EDT - 1 day ago

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026

2026-05-12T12:59:26.000Z - 6 days ago

Design Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-05-12T10:39:30.000Z - 6 days ago

Design Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-05-04T11:50:12.000Z - 14 days ago

Design Therapeutics price target raised to $21 from $18 at Oppenheimer

2026-04-29T13:52:43.000Z - 19 days ago

Design Therapeutics price target raised to $20 from $12 at Piper Sandler

2026-04-28T20:46:16.000Z - 20 days ago

Design Therapeutics reports Q1 EPS (29c), consensus (33c)

Apr 28, 2026, 4:01 PM EDT - 20 days ago

Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Apr 28, 2026, 8:30 AM EDT - 20 days ago

Design Therapeutics Earnings Call Transcript: Q1 2026

2026-04-16T19:41:28.000Z - 4 weeks ago

Design Therapeutics management to meet with Oppenheimer

2026-04-16T19:40:17.000Z - 4 weeks ago

Design Therapeutics management to meet with Oppenheimer

2026-04-02T14:43:30.000Z - 6 weeks ago

Design Therapeutics management to meet with Oppenheimer

2026-03-16T00:15:04.000Z - 2 months ago

Design Therapeutics initiated with a Buy at Jefferies

Mar 10, 2026, 2:20 PM EDT - 2 months ago

Design Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-10T11:40:37.000Z - 2 months ago

Design Therapeutics price target raised to $14 from $13 at RBC Capital

2026-03-09T20:16:56.000Z - 2 months ago

Design Therapeutics reports Q4 EPS (27c), consensus (35c)

Mar 9, 2026, 4:01 PM EDT - 2 months ago

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Feb 25, 2026, 1:20 PM EST - 2 months ago

Design Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 8:00 AM EST - 3 months ago

Design Therapeutics to Participate in Upcoming Investor Conferences

2026-01-07T11:37:08.000Z - 4 months ago

Design Therapeutics initiated with an Outperform at Oppenheimer

Dec 4, 2025, 10:00 AM EST - 5 months ago

Design Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:30 PM EST - 5 months ago

Design Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-03T14:15:09.000Z - 5 months ago

Craig-Hallum bullish on Design Therapeutics, initiates with a Buy

2025-12-03T12:40:14.000Z - 5 months ago

Design Therapeutics initiated with a Buy at Craig-Hallum

Nov 5, 2025, 4:01 PM EST - 6 months ago

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Sep 10, 2025, 4:01 PM EDT - 8 months ago

Design Therapeutics Appoints Justin Gover to Board of Directors

Sep 4, 2025, 10:55 AM EDT - 9 months ago

Design Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Aug 7, 2025, 4:01 PM EDT - 10 months ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

Jun 4, 2025, 2:35 PM EDT - 1 year ago

Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

May 28, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

May 7, 2025, 4:01 PM EDT - 1 year ago

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

May 1, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Apr 21, 2025, 4:01 PM EDT - 1 year ago

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Design Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 7:07 AM EDT - 1 year ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Dec 3, 2024, 11:30 AM EST - 1 year ago

Design Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 5:00 AM EST - 1 year ago

Design Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Nov 7, 2024, 4:01 PM EST - 1 year ago

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Sep 19, 2024, 12:45 PM EDT - 1 year ago

Design Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

May 15, 2024, 11:30 AM EDT - 2 years ago

Design Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 2 years ago

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

May 7, 2024, 6:30 AM EDT - 2 years ago

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Design Therapeutics Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:01 PM EDT - 2 years ago

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 6:30 AM EDT - 2 years ago

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Nov 13, 2023, 4:05 PM EST - 2 years ago

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Aug 15, 2023, 8:17 AM EDT - 2 years ago

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Aug 14, 2023, 4:05 PM EDT - 3 years ago

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:01 PM EDT - 3 years ago

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Transcript: Study Update

May 31, 2023, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

May 9, 2023, 4:05 PM EDT - 3 years ago

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

Apr 24, 2023, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Mar 14, 2023, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 8, 2023, 6:30 AM EST - 3 years ago

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Dec 7, 2022, 4:01 PM EST - 3 years ago

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Nov 3, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Oct 17, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Sep 22, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Aug 8, 2022, 4:05 PM EDT - 4 years ago

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Aug 3, 2022, 6:30 AM EDT - 4 years ago

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Jun 1, 2022, 6:30 AM EDT - 4 years ago

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 9, 2022, 4:05 PM EDT - 4 years ago

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Mar 30, 2022, 6:30 AM EDT - 4 years ago

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Mar 10, 2022, 4:02 PM EST - 4 years ago

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Mar 9, 2022, 6:30 AM EST - 4 years ago

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Feb 28, 2022, 4:05 PM EST - 4 years ago

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Feb 10, 2022, 6:30 AM EST - 4 years ago

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Feb 1, 2022, 4:05 PM EST - 4 years ago

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

SuperGreenToday May. 19 at 12:55 AM

0 · Reply

Arcides May. 18 at 5:28 PM

$DSGN down 51% from premarket high

1 · Reply

Olivia_Strickland May. 18 at 4:35 PM

1 · Reply

Arcides May. 18 at 3:43 PM

$DSGN

0 · Reply

laaarsas May. 18 at 3:32 PM

$DSGN Why down today?

0 · Reply

OptionRunners May. 18 at 12:58 PM

$DSGN +10% on data

0 · Reply

notreload_ai May. 18 at 12:45 PM

0 · Reply

OpenOutcrier May. 18 at 12:40 PM

$DSGN (+7.9% pre) Design Therapeutics reports positive trial data for Friedreich ataxia drug https://ooc.bz/l/102670

0 · Reply

focafoca99 May. 17 at 10:44 PM

$DSGN hosts a webcast on May 18 to review RESTORE-FA trial data for DT-216P2.

0 · Reply

AlertsAndNews May. 17 at 10:06 PM

0 · Reply

NVDAMillionaire May. 14 at 7:49 AM

$DSGN Excellent article that nails exactly where DSGN stands right now. So if you want to update your DSGN knowledge or get acquainted with DSGN, this is a must read. https://everyticker.com/quote/DSGN/analysis/design-therapeutics-platform-validation-at-the-crossroads-of-capital-efficiency-and-clinical-velocity-nasdaq-dsgn

0 · Reply

Doozio May. 6 at 6:54 PM

Chop chop huckleberries it was all by $DSGN ONTO 🐒🍌🧠⏰♾️

0 · Reply

OptionRunners May. 6 at 6:43 PM

$DSGN massive call spread opening. Almost $7M in premium.

1 · Reply

PenkeInvesting May. 4 at 3:09 AM

Fundamental analysis of $DSGN (Design Therapeutics, Inc.) based on financial data and reported results. #DSGN #Design

0 · Reply

OfficialStocktwitsUser Apr. 30 at 8:46 PM

$DSGN RSI: 59.02, MACD: 0.7243 Vol: 0.86, MA20: 12.84, MA50: 11.38 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockScanners Apr. 30 at 12:56 AM

$DSGN keep watch if this holds above 15.54

0 · Reply

ScorpionScarlet Apr. 29 at 7:33 PM

$DSGN what a beast! Up 350% in 1 year! Green non stop! 🥳🥳💕

0 · Reply

RETAlerts Apr. 29 at 4:23 PM

$DSGN moving on Kaleidescape hardware wins. Strato E and Mini Terra Prime getting recognition is driving real momentum here. Pr...

0 · Reply

d_risk Apr. 28 at 8:24 PM

$DSGN - Design Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +273.7% above peer average (45,018 vs 12,048 across 652 peers). DSGN’s 10-Q layers on a full biopharma risk slate: new flags on bank failures impacting cash, heavy and uncertain clinical and regulatory hurdles (including ex-US data, designations, safety and enrollment), dependence on third parties and IP fragility, commercialization and reimbursement challenges, extensive stock/market structure risks, cyber and operational threats, and broader macro/geopolitical and governance vulnerabilities. 🟢 Added 🟠 Removed https://d-risk.ai/DSGN/10-Q/2026-04-28

0 · Reply

focafoca99 Apr. 1 at 9:47 PM

$DSGN added David Shapiro to the board and immediately slotted him onto the nominating committee.

0 · Reply

notreload_ai Mar. 16 at 4:45 PM

$DSGN , $RVMD , $KYMR , $IMTX , $INSM ... Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228). https://notreload.xyz/jefferies-biotech-buys-dsgn-rvmd-kymr-more-in-2026/

0 · Reply

Market Cap	897.51M
Revenue (ttm)	0.00
Net Income (ttm)	-69.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,646,200
Avg Vol	587,602
Day's Range	N/A - N/A
Shares Out	62.46M
Stochastic %K	10%
Beta	1.73
Analysts	Strong Sell
Price Target	$17.17